Abstract
Purpose. To examine the pharmacokinetic features and metabolism of calphostin C, a naturally occurring perylenequinone with potent antileukemic activity.
Methods. HPLC-based quantitative detection methods were used to measure calphostin C levels in lysates of leukemic cells and in plasma of mice treated with calphostin C. The plasma concentration-time data were analyzed using the WinNonlin program. In vitro esterases and a microsome P450 preparation in conjunction with a LC-MS(API-EI) system were used to study the metabolism of calphostin C.
Results. An intracellular exposure level (AUC0−6h) of 257 μM·h was achieved after in vitro treatment of NALM-6 cells with calphostin C at a 5 μM final concentration in culture medium. After intraperitoneal (i.p.) injection of a 40 mg/kg nontoxic bolus dose of calphostin C, the estimated Cmax was 2.9 μM, which is higher than the effective in vitro concentration of calphostin C against leukemic cells. Drug absorption after i.p. administration was rapid with an absorption half-life of 24.2 min and the estimated tmax was 63.0 min. Calphostin C was cleared with an elimination half-life of 91.3 min. An inactive and smaller metabolite (calphostin B) was detected in plasma of calphostin C-treated mice with a tmax of 41.3 min. Esterase (but not P450) treatment of calphostin C in vitro yielded an inactive metabolite (calphostin B) of the same size and elution profile.
Conclusions. Target plasma calphostin C concentrations of potent antileukemic activity can be reached in mice at nontoxic dose levels. This pilot pharmacokinetic study of calphostin C combined with the availability of the described quantitative HPLC method for its detection in cells and plasma provide the basis for future preclinical evaluation of calphostin C and its potential as an anti-leukemic drug.
Similar content being viewed by others
REFERENCES
M. E. Trigg, P. S. Gaynon, and F. M. Uckun. Acute lymphoblastic leukemia in children, in J. F. Holland, Emile Fry III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (Editor), Cancer Medicine. Fourth Edition. 1996, Ch. 164, p. 2945.
E. Kobayashi, H. Nakano, M. Morimoto, and T. Tamaoki. Calphostin C (UCN-1028 C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:548–553 (1989).
E. Kobayashi, K. Ando, H. Nakano, T. Iida, H. Ohno, M. Morimoto, and T. Tamaoki. Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C. J. Antibiotics. 42:1470–1474 (1989).
H. Ikemoto, E. Tani, T. Matsumoto, A. Nakano, and J. Furuyama. Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. J. Neurosurg. 83:1008–1016 (1995).
D. M. Zhu, R. K. Narla, W. H Fang, N. C. Chia, and F. M. Uckun. Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. Clin. Cancer Res. 4:2967–76 (1998).
D. M. Zhu, W. H. Fang, R. K. Narla, and F. M. Uckun. A requirement for protein kinase C inhibition for calcium-triggered apoptosis in acute lymphoblastic leukemia cells. Clin. Cancer Res. 5:355–360 (1999).
C. L. Chen, H. Chen, D. M. Zhu, and F. M. Uckun. Quantitative high-performance liquid chromatography-based detection method for calphostin C, a naturally occurring perylenequinone with potent antileukemic activity. J. Chromatogr. B. 724:157–162 (1999).
F. M Uckun, K. G. Waddick, S. Mahajan, X. Jun, M. Takata, J. Bolen, and T. Kurosak. Bruton's tyrosine kinase as a mediator of radiation-induced apoptosis in B-lineage lymphoid cells. Science 22:1096–1100 (1996).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, CL., Tai, HL., Zhu, DM. et al. Pharmacokinetic Features and Metabolism of Calphostin C, A Naturally Occurring Perylenequinone with Antileukemic Activity. Pharm Res 16, 1003–1009 (1999). https://doi.org/10.1023/A:1018923430094
Issue Date:
DOI: https://doi.org/10.1023/A:1018923430094